Holen Sie sich die Stockscreener-App
0.00
100.00%
-16.50
Schlusskurs vom Vortag:
$16.50
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$159.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$23.00
Invizyne Technologies Inc Stock (IZTC) Company Profile
Firmenname
Invizyne Technologies Inc
Sektor
Branche
Telefon
(626) - 415 - 1488
Adresse
750 ROYAL OAKS DR, MONROVIA
Vergleichen Sie IZTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IZTC
Invizyne Technologies Inc
|
0.00 | 159.70M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Invizyne Technologies Inc Aktie (IZTC) Neueste Nachrichten
Comparing Invizyne Technologies (NASDAQ:IZTC) and Caribou Biosciences (NASDAQ:CRBU) - Defense World
Invizyne Technologies Inc.’s (NASDAQ:IZTC) Lock-Up Period Set To Expire on May 12th - Defense World
Geode Capital Management LLC Makes New Investment in Invizyne Technologies Inc. (NASDAQ:IZTC) - Defense World
Bringing clarity and precision to the cell-free space by introducing exozymes - markets.businessinsider.com
Head-To-Head Contrast: iTeos Therapeutics (NASDAQ:ITOS) & Invizyne Technologies (NASDAQ:IZTC) - Defense World
EXoZymes Inc. Announces Its Latest Initiative BioClick - MarketScreener
Contrasting Invizyne Technologies (NASDAQ:IZTC) and C4 Therapeutics (NASDAQ:CCCC) - Defense World
EXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - MarketScreener
EXoZymes, Inc. Announces Management Changes -February 21, 2025 at 04:37 pm EST - Marketscreener.com
ExoZymes Inc. appoints new board member and chairman By Investing.com - Investing.com Australia
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - The Manila Times
eXoZymes Inc. Announces Leadership Changes and Rebranding Following Transition from Invizyne Technologies - Nasdaq
EXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering - Marketscreener.com
Can This AI-Powered Enzyme Company Transform the Future of Biotech? Nasdaq's Newest IPO Makes Bold Claims - StockTitan
Positive week for Invizyne Technologies, Inc. (NASDAQ:EXOZ) institutional investors who control 42% of the company - Simply Wall St
Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC) - Yahoo Finance UK
Invizyne Technologies, Inc. will Change its Name to eXoZymes, Inc -February 12, 2025 at 12:00 am EST - Marketscreener.com
Invizyne Technologies, Inc. will Change its Ticker to EXOZ from IZTC -February 12, 2025 at 12:00 am EST - Marketscreener.com
What’s in a Name: Out with Invizyne, In with eXoZymes - Genetic Engineering & Biotechnology News
Rebranding Invizyne to eXoZymes Signifies a Sustainable - GlobeNewswire
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging - EIN News
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ - MSN
Invizyne announces corporate name change to eXoZymes - MSN
Invizyne Technologies Announces Name Change To EXoZymes - Nasdaq
MDBHMDB Capital Holdings LLC-A Latest Stock News & Market Updates - StockTitan
Invizyne Technologies Changes Name to eXoZymes -February 10, 2025 at 11:31 am EST - Marketscreener.com
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ By Investing.com - Investing.com Nigeria
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - GlobeNewswire
Major Biotech Rebrand: Invizyne Becomes eXoZymesStrategic Move in Enzyme Manufacturing Space - Stock Titan
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock - MSN
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock By Investing.com - Investing.com Australia
Investors on Edge! What Invizyne’s Market Entry Means for Biotech’s Future - Jomfruland.net
Invizyne Technologies Inc.'s (NASDAQ:IZTC) Quiet Period To End on December 23rd - MarketBeat
Invizyne Technologies Inc.’s Quiet Period Set To Expire on December 23rd (NASDAQ:IZTC) - Defense World
Invizyne Technologies selected for $2 million project to advance SAF capabilities - Biomass Magazine
Invizyne Technologies Inc trading halted, volatility trading pause - TipRanks
Invizyne Technologies Inc trading resumes - Nasdaq
MDB Capital Holdings Provides Third Quarter 2024 Update - Marketscreener.com
Invizyne Technologies (IZTC) Income Statement & Balance Sheet 2024 - MarketBeat
MDB Capital Q3: Mayo Clinic Deal, AUM Surges to $28M, Invizyne IPO Success - StockTitan
Opening Day: Invizyne Technologies jumps after IPO - MSN
Invizyne technologies CEO acquires shares worth $22,022 By Investing.com - Investing.com Australia
Invizyne technologies CEO acquires shares worth $22,022 - Investing.com
Faculty in the News – James Bowie - UCLA – Chemistry and Biochemistry
Finanzdaten der Invizyne Technologies Inc-Aktie (IZTC)
Es liegen keine Finanzdaten für Invizyne Technologies Inc (IZTC) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Invizyne Technologies Inc-Aktie (IZTC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Heltzen Michael | Chief Executive Officer |
Jan 16 '25 |
Buy |
10.72 |
121 |
1,297 |
2,105 |
| Heltzen Michael | Chief Executive Officer |
Nov 15 '24 |
Buy |
11.10 |
1,984 |
22,022 |
1,984 |
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):